Guardant Health Inc. (GH)
NASDAQ: GH
· Real-Time Price · USD
47.23
-2.30 (-4.64%)
At close: Apr 30, 2025, 3:59 PM
51.30
8.61%
Pre-market: May 01, 2025, 07:26 AM EDT
-4.64% (1D)
| Bid | 50.5 |
| Market Cap | 5.83B |
| Revenue (ttm) | 774M |
| Net Income (ttm) | -416.55M |
| EPS (ttm) | -3.56 |
| PE Ratio (ttm) | -13.27 |
| Forward PE | -19.05 |
| Analyst | Buy |
| Ask | 51.81 |
| Volume | 2,848,164 |
| Avg. Volume (20D) | 2,167,014 |
| Open | 47.40 |
| Previous Close | 49.53 |
| Day's Range | 46.78 - 48.40 |
| 52-Week Range | 17.85 - 50.89 |
| Beta | 1.45 |
About GH
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test fo...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Oct 4, 2018
Employees 1,999
Stock Exchange NASDAQ
Ticker Symbol GH
Website https://guardanthealth.com
Analyst Forecast
According to 20 analyst ratings, the average rating for GH stock is "Buy." The 12-month stock price forecast is $52, which is an increase of 10.09% from the latest price.
Stock ForecastsEarnings Surprise
Guardant Health has released their quartely earnings
on Apr 30, 2025:
Just now
Guardant Health shares are trading higher after th...
Unlock content with
Pro Subscription
Just now
-4.64%
Guardant Health shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sales guidance.
